TDOC INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Teladoc Health, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

21.05.24 14:46 Uhr

Werte in diesem Artikel
Aktien

9,88 EUR 0,94 EUR 10,45%

NEW YORK, May 21, 2024 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Teladoc Health, Inc. ("Teladoc" or "the Company") (NYSE: TDOC) and certain of its officers.

Bronstein, Gewirtz & Grossman, LLC

Class Definition:

This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Teladoc securities between November 2, 2022 and February 20, 2024, inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: bgandg.com/TDOC.

Case Details:

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements and/or failed to disclose material adverse information regarding the Company, including allegations that: (1) Teladoc continued to expand its marketing spend throughout 2023, despite public assurances that it would pull back its advertising spending; (2) increased marketing spend on BetterHelp deteriorated Teladoc's revenue, with little return for that investment; (3) despite Teladoc's acknowledgment that increased advertising spend would be marginally inefficient due to market saturation, it continued to grow its advertising spend in the BetterHelp business; and (4) despite public statements that there remained "a long runway" for BetterHelp membership growth, BetterHelp's membership stagnated and then decreased in 2023, due to market saturation, largely due to BetterHelp's own marketing.

What's Next?

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm's site: bgandg.com/TDOC or you may contact Peretz Bronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660. If you suffered a loss in Teladoc you have until July 16, 2024, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as lead plaintiff.

There is No Cost to You

We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.

Why Bronstein, Gewirtz & Grossman:

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.

Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC

Peretz Bronstein or Nathan Miller,

332-239-2660 | info@bgandg.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/tdoc-investor-alert-bronstein-gewirtz--grossman-llc-announces-that-teladoc-health-inc-investors-with-substantial-losses-have-opportunity-to-lead-class-action-lawsuit-302151239.html

SOURCE Bronstein, Gewirtz & Grossman, LLC

Ausgewählte Hebelprodukte auf Teladoc

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Teladoc

NameHebelKOEmittent
NameHebelKOEmittent
Werbung

Nachrichten zu Teladoc Inc

Analysen zu Teladoc Inc

DatumRatingAnalyst
02.11.2018Teladoc BuyChardan Capital Markets
03.08.2018Teladoc BuyChardan Capital Markets
05.06.2018Teladoc BuyCanaccord Adams
15.03.2018Teladoc HoldDeutsche Bank AG
28.02.2018Teladoc BuyChardan Capital Markets
DatumRatingAnalyst
02.11.2018Teladoc BuyChardan Capital Markets
03.08.2018Teladoc BuyChardan Capital Markets
05.06.2018Teladoc BuyCanaccord Adams
28.02.2018Teladoc BuyChardan Capital Markets
08.12.2017Teladoc BuyDeutsche Bank AG
DatumRatingAnalyst
15.03.2018Teladoc HoldDeutsche Bank AG
18.09.2017Teladoc NeutralRobert W. Baird & Co. Incorporated
DatumRatingAnalyst

Keine Analysen im Zeitraum eines Jahres in dieser Kategorie verfügbar.

Eventuell finden Sie Nachrichten die älter als ein Jahr sind im Archiv

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Teladoc Inc nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"